Alder Biopharmaceuticals

Alder Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Alder specializes in therapeutic monoclonal antibodies.

Alder Biopharmaceuticals
NASDAQ: ALDR
Russell 2000 Component

In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million .[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]

As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4][5]

References
  1. "Alder BioPharmaceuticals stock flat after unexciting IPO". geekwire.com. 8 May 2014. Retrieved 24 August 2017.
  2. "Deals this week: Onconova Therapeutics, Humorigin Biotechnology, Zosano Pharma". Drug Development Technology. Kable. 2 February 2018. Retrieved 3 February 2018.
  3. "Alder Biopharmaceuticals Inc - Company Profile and News". Bloomberg.com. Retrieved 2019-05-21.
  4. Kilgore, Tomi (2019-09-16). "Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal". Market Watch. Retrieved 2019-10-21.
  5. staff, Seattle Times business (2019-09-16). "Alder BioPharma, Bothell developer of migraine-prevention drug, acquired for up to $2 billion". The Seattle Times. Retrieved 2020-06-18.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.